Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

Marek Lommatzsch; Katharina Blumchen; Lisa A. Beck; Jean Bousquet; Guy G. Brusselle; Wytske J. Fokkens; Eckard Hamelmann; Susanne Lau; Hagen Ott; Oliver Pfaar; Hugh A. Sampson; Josef S. Smolen; Christian Taube; Ingo H. Tarner; Martin Wagenmann; Thomas Werfel; Margitta Worm; Harald Renz

doi:10.1016/j.eclinm.2024.103050

Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

Marek Lommatzsch, Katharina Blumchen, Lisa A. Beck, Jean Bousquet, Guy G. Brusselle, Wytske J. Fokkens, Eckard Hamelmann, Susanne Lau, Hagen Ott, Oliver Pfaar, Hugh A. Sampson, Josef S. Smolen, Christian Taube, Ingo H. Tarner, Martin Wagenmann, Thomas Werfel, Margitta Worm, Harald Renz

Research output: Contribution to journal › Review article › peer-review

Abstract

Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None.

Original language	English
Article number	103050
Journal	eClinicalMedicine
Volume	80
DOIs	https://doi.org/10.1016/j.eclinm.2024.103050
State	Published - Feb 2025

Keywords

Disease modification
Remission
Type 2 inflammation

Access to Document

10.1016/j.eclinm.2024.103050

Cite this

Lommatzsch, M., Blumchen, K., Beck, L. A., Bousquet, J., Brusselle, G. G., Fokkens, W. J., Hamelmann, E., Lau, S., Ott, H., Pfaar, O., Sampson, H. A., Smolen, J. S., Taube, C., Tarner, I. H., Wagenmann, M., Werfel, T., Worm, M., & Renz, H. (2025). Roads to remission: evolving treatment concepts in type 2 inflammatory diseases. eClinicalMedicine, 80, Article 103050. https://doi.org/10.1016/j.eclinm.2024.103050

@article{092c111760544a1db4c60b74b6825e50,

title = "Roads to remission: evolving treatment concepts in type 2 inflammatory diseases",

abstract = "Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None.",

keywords = "Disease modification, Remission, Type 2 inflammation",

author = "Marek Lommatzsch and Katharina Blumchen and Beck, {Lisa A.} and Jean Bousquet and Brusselle, {Guy G.} and Fokkens, {Wytske J.} and Eckard Hamelmann and Susanne Lau and Hagen Ott and Oliver Pfaar and Sampson, {Hugh A.} and Smolen, {Josef S.} and Christian Taube and Tarner, {Ingo H.} and Martin Wagenmann and Thomas Werfel and Margitta Worm and Harald Renz",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2025",

month = feb,

doi = "10.1016/j.eclinm.2024.103050",

language = "English",

volume = "80",

journal = "eClinicalMedicine",

issn = "2589-5370",

publisher = "Elsevier Ltd.",

}

Lommatzsch, M, Blumchen, K, Beck, LA, Bousquet, J, Brusselle, GG, Fokkens, WJ, Hamelmann, E, Lau, S, Ott, H, Pfaar, O, Sampson, HA, Smolen, JS, Taube, C, Tarner, IH, Wagenmann, M, Werfel, T, Worm, M & Renz, H 2025, 'Roads to remission: evolving treatment concepts in type 2 inflammatory diseases', eClinicalMedicine, vol. 80, 103050. https://doi.org/10.1016/j.eclinm.2024.103050

TY - JOUR

T1 - Roads to remission

T2 - evolving treatment concepts in type 2 inflammatory diseases

AU - Lommatzsch, Marek

AU - Blumchen, Katharina

AU - Beck, Lisa A.

AU - Bousquet, Jean

AU - Brusselle, Guy G.

AU - Fokkens, Wytske J.

AU - Hamelmann, Eckard

AU - Lau, Susanne

AU - Ott, Hagen

AU - Pfaar, Oliver

AU - Sampson, Hugh A.

AU - Smolen, Josef S.

AU - Taube, Christian

AU - Tarner, Ingo H.

AU - Wagenmann, Martin

AU - Werfel, Thomas

AU - Worm, Margitta

AU - Renz, Harald

PY - 2025/2

Y1 - 2025/2

N2 - Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None.

AB - Non-communicable diseases (NCDs) characterised by type 2 inflammation, including asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, food allergies and eosinophilic esophagitis, are increasing in prevalence worldwide. Currently, there is a major paradigm shift in the management of these diseases, towards the concept of disease modification and the treatment goal remission, regardless of severity and age. Remission as a treatment goal in chronic inflammatory NCDs was first introduced in rheumatoid arthritis, and then adopted in other non-type 2 inflammatory diseases. Among diseases with type 2 Inflammation, this concept is novel and currently most advanced in asthma. This new paradigm has been developed based on a better understanding of the pathophysiology of type 2 inflammation and the advent of highly effective drugs selectively interfering with type 2 pathways. Here, we review the evolution of the new remission concepts in type 2 inflammatory diseases and discuss associated challenges and future research needs. Funding: None.

KW - Disease modification

KW - Remission

KW - Type 2 inflammation

UR - http://www.scopus.com/inward/record.url?scp=85214290684&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2024.103050

DO - 10.1016/j.eclinm.2024.103050

M3 - Review article

AN - SCOPUS:85214290684

SN - 2589-5370

VL - 80

JO - eClinicalMedicine

JF - eClinicalMedicine

M1 - 103050

ER -

Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

Abstract

Keywords

Access to Document

Fingerprint

Cite this